Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437381 | 0.87 | MAPT (0.45) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL14032548 | 0.79 | LMNA (0.43) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL4434559 | 0.79 | MAPT (0.45) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL18099304 | 0.79 | MAPT (0.45) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL4432546 | 0.79 | MAPT (0.48) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL1172369 | 0.78 | MAPT (0.54) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL2712653 | 0.78 | MAPT (0.54) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL5132397 | 0.78 | MAPT (0.59) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL5132587 | 0.78 | AGXT (0.45) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL27794469 | 0.77 | KMT2A (0.45) | MAPTKMT2AMAPK1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | MAPT 3593/4885KMT2A 2230/4885MAPK1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.